Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Debt (2023 - 2025)

OptimizeRx (OPRX) has disclosed Non-Current Debt for 3 consecutive years, with $21.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 30.49% to $21.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.4 million through Dec 2025, down 30.49% year-over-year, with the annual reading at $21.4 million for FY2025, 30.49% down from the prior year.
  • Non-Current Debt hit $21.4 million in Q4 2025 for OptimizeRx, down from $24.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $34.2 million in Q4 2023 to a low of $21.4 million in Q4 2025.
  • Historically, Non-Current Debt has averaged $29.3 million across 3 years, with a median of $30.8 million in 2024.
  • Biggest YoY gain for Non-Current Debt was 9.94% in 2025; the steepest drop was 30.49% in 2025.
  • Year by year, Non-Current Debt stood at $34.2 million in 2023, then decreased by 9.98% to $30.8 million in 2024, then plummeted by 30.49% to $21.4 million in 2025.
  • Business Quant data shows Non-Current Debt for OPRX at $21.4 million in Q4 2025, $24.8 million in Q3 2025, and $25.1 million in Q2 2025.